Articoli correlati a Blood Stem Cell Transplantation: 77

Blood Stem Cell Transplantation: 77 ISBN 13: 9780792342601

Blood Stem Cell Transplantation: 77 - Rilegato

 
9780792342601: Blood Stem Cell Transplantation: 77

Sinossi

Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come.
Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/or expand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors.
Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed.
The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigation and for the clinical experiments they generate will be required if we are to go forward. Blood Stem Cell Transplantation lays the foundation for many of these future advances; it is incumbent upon us all to insure its realization.

Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.

Contenuti

Preface; J.N. Winter. Developments in Immuno-, Molecular and Cell Biology: Implications for Clinical Stem Cell Transplantation. Gene Therapy of Solid Tumor and Hematopoietic Neoplasms; C. Bachier, A.B. Deisseroth. Post-Bone Marrow Transplant Use of Immunotherapy; U.N. Verma, et al. Graft-Versus-Leukemia Effect of Allogeneic Bone Marrow Transplantation and Donor Mononuclear Cell Infusions; D.L. Porter, J.H. Antin. Graft-Versus-Host Disease: Implications from Basic Immunology for Prophylaxis and Treatment; G.B. Vogelsang. Detection of Minimal Residual Disease: Implications for Bone Marrow Transplantation; J.G. Gribben, J.L. Schultze. The Use of Radiolabeled Antibodies in Bone Marrow Transplantation for Hematologic Malignancies; D.C. Matthews, et al. Sources of Hematopoietic Stem Cells and Their Ex Vivo Expansion. Peripheral Blood Stem Cell Harvesting and CD34-Positive Cell Selection; E.J. Shpall, et al. Allogeneic Umbilical Cord Blood Transplantation; J.E. Wagner. The Use of Unrelated Donors for Bone Marrow Transplantation; G. Tricot. Reducing the Toxicity Associated with Hematopoietic Stem Cell Transplantation. Supportive Care in Bone Marrow Transplantation: Pulmonary Complications; S.W. Crawford. Recombinant Cytokines and Hematopoietic Growth Factors in Allogeneic and Autologous Bone Marrow Transplantation; H.M. Lazarus. Clinical Applications: Continued Progress and New Frontiers. Bone Marrow Transplantation in Thalassemia; G. Lucarelli, et al. Immune Ablation and Hematopoietic Stem Cell Rescue for Severe Autoimmune Diseases (SADS); R.K. Burt. Autologous Bone Marrow Transplantation in Pediatric Solid Tumors; M. Kletzel, A.R. Kim. Autologous Stem Cell Transplantation for the Treatment of Chronic Myelogenous Leukemia; R. Bhatia, P.B. McGlave. A New Challenge for the Field of Stem Cell Transplantation: Financial Constraints. Health Care Economics and Bone Marrow Transplantation; I. Westerman, et al. Index.

Product Description

Book by None

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

Compra usato

Condizioni: buono
416 pp., bibliography, index. ex-library...
Visualizza questo articolo

EUR 4,12 per la spedizione in U.S.A.

Destinazione, tempi e costi

Altre edizioni note dello stesso titolo

9781461379164: Blood Stem Cell Transplantation: 77

Edizione in evidenza

ISBN 10:  1461379164 ISBN 13:  9781461379164
Casa editrice: Springer, 2012
Brossura

Risultati della ricerca per Blood Stem Cell Transplantation: 77

Foto dell'editore

ISBN 10: 0792342607 ISBN 13: 9780792342601
Antico o usato Rilegato

Da: Masalai Press, Oakland, CA, U.S.A.

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Hardcover. Condizione: Good. 416 pp., bibliography, index. ex-library, label & abrasion on spine, cover partly-faded, stamps on outside edges, spine skewed, labels inside back cover, text unmarked, binding OK 0.0. Codice articolo 0792342607AMA092912

Contatta il venditore

Compra usato

EUR 88,44
Convertire valuta
Spese di spedizione: EUR 4,12
In U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Foto dell'editore

Unbekannt
Editore: Springer US, 1997
ISBN 10: 0792342607 ISBN 13: 9780792342601
Antico o usato Rilegato

Da: Buchpark, Trebbin, Germania

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Condizione: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher. Codice articolo 1828906/2

Contatta il venditore

Compra usato

EUR 79,97
Convertire valuta
Spese di spedizione: EUR 105,00
Da: Germania a: U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Foto dell'editore

Winter, Jane N.
Editore: Springer, 1997
ISBN 10: 0792342607 ISBN 13: 9780792342601
Nuovo Rilegato

Da: Toscana Books, AUSTIN, TX, U.S.A.

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Hardcover. Condizione: new. Excellent Condition.Excels in customer satisfaction, prompt replies, and quality checks. Codice articolo Scanned0792342607

Contatta il venditore

Compra nuovo

EUR 208,76
Convertire valuta
Spese di spedizione: EUR 3,69
In U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Foto dell'editore

Winter, Jane N., ed.
ISBN 10: 0792342607 ISBN 13: 9780792342601
Antico o usato Rilegato

Da: Tiber Books, Cockeysville, MD, U.S.A.

Valutazione del venditore 4 su 5 stelle 4 stelle, Maggiori informazioni sulle valutazioni dei venditori

Hardcover. Condizione: Very Good. 8vo, hardcover. No dj. Vg condition. Non-circulating ex-lib copy w/ label removed from endpaper, spine label removed, leaving outline; spine slightly faded (lettering fully visible), contents clean, binding tight. xiv, 416 p., illus. Codice articolo 1091007.64

Contatta il venditore

Compra usato

EUR 221,13
Convertire valuta
Spese di spedizione: EUR 4,71
In U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Immagini fornite dal venditore

Winter, Jane N.
Editore: Springer US, 1997
ISBN 10: 0792342607 ISBN 13: 9780792342601
Nuovo Rilegato
Print on Demand

Da: moluna, Greven, Germania

Valutazione del venditore 4 su 5 stelle 4 stelle, Maggiori informazioni sulle valutazioni dei venditori

Gebunden. Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances . Codice articolo 5967915

Contatta il venditore

Compra nuovo

EUR 399,55
Convertire valuta
Spese di spedizione: EUR 48,99
Da: Germania a: U.S.A.
Destinazione, tempi e costi

Quantità: Più di 20 disponibili

Aggiungi al carrello

Foto dell'editore

Editore: Springer, 1997
ISBN 10: 0792342607 ISBN 13: 9780792342601
Nuovo Rilegato

Da: Ria Christie Collections, Uxbridge, Regno Unito

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Condizione: New. In. Codice articolo ria9780792342601_new

Contatta il venditore

Compra nuovo

EUR 479,16
Convertire valuta
Spese di spedizione: EUR 13,79
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

Quantità: Più di 20 disponibili

Aggiungi al carrello

Immagini fornite dal venditore

Jane N. Winter
Editore: Springer US Mrz 1997, 1997
ISBN 10: 0792342607 ISBN 13: 9780792342601
Nuovo Rilegato
Print on Demand

Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/or expand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors. Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed. The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigation and for the clinical experiment 436 pp. Englisch. Codice articolo 9780792342601

Contatta il venditore

Compra nuovo

EUR 481,49
Convertire valuta
Spese di spedizione: EUR 23,00
Da: Germania a: U.S.A.
Destinazione, tempi e costi

Quantità: 2 disponibili

Aggiungi al carrello

Foto dell'editore

Jane N. Winter
ISBN 10: 0792342607 ISBN 13: 9780792342601
Nuovo Rilegato

Da: Grand Eagle Retail, Bensenville, IL, U.S.A.

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Hardcover. Condizione: new. Hardcover. This text seeks to convey the extent and significance of a current development in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations, for example, the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy.Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is also detailed. Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/orexpand the graft. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Codice articolo 9780792342601

Contatta il venditore

Compra nuovo

EUR 520,98
Convertire valuta
Spese di spedizione: GRATIS
In U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Immagini fornite dal venditore

Jane N. Winter
ISBN 10: 0792342607 ISBN 13: 9780792342601
Nuovo Rilegato

Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Buch. Condizione: Neu. Neuware -Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come.Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/orexpand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors.Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed.The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigatiSpringer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 436 pp. Englisch. Codice articolo 9780792342601

Contatta il venditore

Compra nuovo

EUR 481,49
Convertire valuta
Spese di spedizione: EUR 60,00
Da: Germania a: U.S.A.
Destinazione, tempi e costi

Quantità: 2 disponibili

Aggiungi al carrello

Immagini fornite dal venditore

Jane N. Winter
Editore: Springer US, Springer US, 1997
ISBN 10: 0792342607 ISBN 13: 9780792342601
Nuovo Rilegato

Da: AHA-BUCH GmbH, Einbeck, Germania

Valutazione del venditore 5 su 5 stelle 5 stelle, Maggiori informazioni sulle valutazioni dei venditori

Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/orexpand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors. Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed. The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigation and for the clinical experiments. Codice articolo 9780792342601

Contatta il venditore

Compra nuovo

EUR 495,00
Convertire valuta
Spese di spedizione: EUR 64,08
Da: Germania a: U.S.A.
Destinazione, tempi e costi

Quantità: 1 disponibili

Aggiungi al carrello

Vedi altre 3 copie di questo libro

Vedi tutti i risultati per questo libro